Treatment Access Protocol For Patients Previously Treated With Dacomitinib On A Clinical Trial In Japan
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 28 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 May 2019.
- 28 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 May 2019.
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.